FIELD: biotechnology and medicine.
SUBSTANCE: antibody-drug conjugate (ADC), an intermediate for its preparation, a method of its preparation and its use are disclosed. The invention relates to an antibody-drug conjugate (ADC), which is Ab-(L3-L2-L1-D)m, where Ab is an antibody; the antibody is an anti-HER2 antibody trastuzumab or a variant thereof, an anti-B7-H3 P2E5 antibody or a variant thereof, or an anti-claudin 18.2 IMAB362 antibody or a variant thereof, an intermediate for its production, a method of its production and its use. ADC has better biological activity, stability and homogeneity, is characterized by reduced toxic and side effects, as well as a faster release rate of the cleavage enzyme in tumor cells.
EFFECT: use of the new ADC may provide a wide use of a cytotoxic drug, in particular camptothecin, in the field of ADC in the treatment of patients with tumors resistant to ADC affecting microtubules.
17 cl, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| DRUG CONJUGATES CONTAINING ANTI-CLAUDIN 18.2 ANTIBODIES | 2016 |
|
RU2841168C2 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| THERAPY FOR TREATING CANCER, INCLUDING ANTIBODIES AGAINST CLAUDIN 18.2 | 2014 |
|
RU2832015C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| ST2 ANTIGEN BINDING PROTEIN | 2021 |
|
RU2841164C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
